 BOTHELL, Wash., March 14, 2022 GLOBE NEWSWIRE -- Athira Pharma, Inc. NASDAQ: ATHA, a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that an overview and update of the fully enrolled ACT-AD Phase 2 clinical trial with Athiras lead development candidate fosgonimeton ATH-1017 in mild-to-moderate Alzheimers disease, will be presented at the International Conference on Alzheimers Parkinson DiseasesTM 2022, ADPDTM 2022 hybrid congress, taking place March 15-20, 2022 virtually and in Barcelona. 